文献速递妇科

聚焦超声消融联合药物治疗外生型子宫腺肌病痛经的回顾性研究

[Investigation of pharmacological regimens combined with focused ultrasound ablation surgery for alleviating dysmenorrhea in extrinsic adenomyosis].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2026-01-01

该回顾性研究纳入87例外生型子宫腺肌病患者,比较FUAS后GnRH-a联合LNG-IUS或序贯地诺孕素两种方案。两组痛经评分均较治疗前显著降低(P均<0.001),不同用药方案是治疗结局的影响因素(P=0.018),长期治疗有效率存在显著差异(P<0.05),均无严重不良反应。

要点

  • FUAS后联合GnRH-a+LNG-IUS或序贯地诺孕素均可有效缓解痛经。
  • 不同术后用药方案影响治疗结局(P=0.018),长期有效率有显著差异。
  • 合并DIE者排除禁忌后可考虑FUAS后GnRH-a序贯地诺孕素方案。

核心结论

  • 外生型子宫腺肌病患者FUAS后辅助GnRH-a联合LNG-IUS或序贯地诺孕素均可有效缓解痛经,取得较满意中远期结局。
  • 用药方案可根据患者病情及个人意愿选择;合并DIE者排除禁忌后可考虑序贯地诺孕素方案。

研究设计与样本

  • 回顾性研究,纳入2019年12月至2023年12月青岛市妇女儿童医院收治的经盆腔MRI诊断的外生型子宫腺肌病患者87例。
  • 按FUAS后用药分为LNG-IUS组53例(GnRH-a+LNG-IUS)和DNG组34例(GnRH-a+地诺孕素),随访12~60个月。

主要发现

  • LNG-IUS组年龄(40.2±5.2)岁,中位痛经评分7分,24例(45.3%,24/53)合并DIE。
  • DNG组年龄(37.1±4.5)岁,中位痛经评分8分,25例(73.5%,25/34)合并DIE。
  • 两组FUAS手术时间、辐照时间、消融率无显著差异(P均>0.05)。
  • 随访两组痛经评分均较治疗前显著降低(P均<0.001),子宫体积均较治疗前显著缩小(P均<0.001)。
  • 不同术后用药方案是治疗结局的影响因素(P=0.018),长期随访两组治疗有效率存在显著差异(P<0.05)。

关键数值与推荐

  • FUAS不良反应均为SIR标准A~B级,药物相关不良反应均为1~2级,两组均无严重不良反应。

临床怎么用

  • 外生型子宫腺肌病FUAS后可依病情及意愿选择GnRH-a联合LNG-IUS或序贯地诺孕素。
  • 合并DIE患者排除禁忌后可优先考虑FUAS后GnRH-a序贯地诺孕素方案。

局限性

  • 回顾性研究,样本量87例,随访12~60个月,非随机分组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate optimal long-term medication regimens combined with focused ultrasound ablation surgery (FUAS) for alleviating dysmenorrhea in patients with extrinsic adenomyosis. Methods: A retrospective research enrolled patients with extrinsic adenomyosis diagnosed by pelvic magnetic resonance imaging and presenting with significant dysmenorrhea symptoms, who underwent FUAS treatment at Qingdao Women and Children's Hospital from December 2019 to December 2023. Patients were divided into two groups based on postoperative treatment regimens: FUAS+gonadotrophin-releasing hormone agonist (GnRH-a)+levonorgestrel-releasing intrauterine system (LNG-IUS) group (Group LNG-IUS) and FUAS+GnRH-a+dienogest group (Group DNG). Clinical characteristics, imaging data, and treatment outcomes of the patients were retrospectively analyzed. Patients were followed up for 12 to 60 months to compare symptom improvement, recurrence rates, and adverse events among different treatment modalities. Results: (1) Clinical data: a total of 87 patients were included, with a mean age of (39.0±5.2) years, a median dysmenorrhea score of 8 and a median course of disease of 5 years. Group LNG-IUS comprised 53 patients with an average age of (40.2±5.2) years and a median dysmenorrhea score of 7 (including 34 cases of severe pain and 17 cases of moderate pain), among whom 24 patients (45.3%, 24/53) had deep infiltrating endometriosis (DIE). Group DNG had 34 patients with an average age of (37.1±4.5) years and a median dysmenorrhea score of 8 (including 21 cases of severe pain and 11 cases of moderate pain), among whom 25 patients (73.5%, 25/34) had DIE. (2) FUAS treatment information: in Group LNG-IUS, the average operation time was (82±29) minutes, with a median irradiation time of 570 s and an average ablation rate of (60.4±22.6)%. In Group DNG, the average operation time was (80±35) minutes, with a median irradiation time of 518 s and an average ablation rate of (58.7±17.8)%. No significant differences were observed in FUAS treatment parameters between the two groups (all P>0.05). (3) Follow-up: dysmenorrhea scores of both groups were significantly lower post treatment (all P<0.001). Different postoperative treatment regimens affected treatment outcomes (P=0.018). Long-term follow-up showed a significant difference in treatment effectiveness between the two groups (P<0.05). Uterine volume had significantly decreased in both groups compared to before treatment (all P<0.001). (4) Adverse events: adverse events during FUAS procedure were all classified as Society of Interventional Radiology (SIR) A-B, and drug-related adverse events were all grade 1-2, with no serious adverse events occurring in either group. Conclusions: Adjuvant therapy with GnRH-a and LNG-IUS or sequential dienogest after FUAS could effectively relieve dysmenorrhea in extrinsic adenomyosis patients, achieving favorable medium- and long-term therapeutic effects. The choice of medication regimen could be based on the patients' condition and personal preference. For patients with coexisting DIE, after contraindications are ruled out, sequential dienogest after FUAS combined with GnRH-a is a viable option. 目的: 探讨聚焦超声消融手术(FUAS)联合药物治疗改善外生型子宫腺肌病患者痛经症状的长期管理用药方案。 方法: 回顾性收集2019年12月至2023年12月青岛市妇女儿童医院收治的有明显痛经症状、经盆腔磁共振成像检查诊断为外生型子宫腺肌病并行FUAS治疗的患者。根据FUAS后的用药方案将患者分为:促性腺激素释放激素激动剂(GnRH-a)+左炔诺孕酮宫内释放系统(LNG-IUS),命名为LNG-IUS组,以及GnRH-a+地诺孕素,命名为DNG组。回顾性分析患者的临床特征、影像学资料及治疗情况,随访12~60个月,比较不同治疗方式的痛经症状改善、复发情况及相关的不良反应。 结果: (1)临床资料:共纳入患者87例(LNG-IUS组53例、DNG组34例),年龄为(39.0±5.2)岁,中位痛经评分为8分,中位病程时间为5年。LNG-IUS组患者的年龄为(40.2±5.2)岁,中位痛经评分为7分(其中中度患者17例、重度患者34例),24例(45.3%,24/53)合并深部浸润型子宫内膜异位症(DIE)。DNG组患者年龄为(37.1±4.5)岁,中位痛经评分为8分(其中中度患者11例、重度患者21例),25例(73.5%,25/34)合并DIE。(2)FUAS治疗信息:LNG-IUS组患者手术时间为(82±29)min,中位辐照时间为570 s,消融率为(60.4±22.6)%。DNG组患者的手术时间为(80±35)min,中位辐照时间为518 s,消融率为(58.7±17.8)%。两组患者FUAS治疗情况均无显著差异(P均>0.05)。(3)随访情况:随访两组患者的痛经评分均较治疗前显著降低(P均<0.001)。FUAS治疗后不同药物治疗方案是治疗结局的影响因素(P=0.018)。两组患者长期随访的治疗有效率存在显著差异(P<0.05)。治疗后随访两组患者的子宫体积均较治疗前显著缩小(P均<0.001)。(4)不良反应:两组患者FUAS治疗期间的相关不良反应均为国际介入放射学会(SIR)标准A~B级,治疗药物的相关不良反应均为1~2级,均无严重不良反应发生。 结论: 外生型子宫腺肌病患者FUAS治疗后辅助GnRH-a联合LNG-IUS或者GnRH-a序贯地诺孕素均可有效缓解痛经,取得较为满意的中远期治疗结局,可根据患者病情及个人意愿进行用药方案的选择。对于合并DIE的患者,排除禁忌后可考虑FUAS治疗后辅助GnRH-a序贯地诺孕素的用药方案。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ding K, Shi QL, Sang CM, et al. [Investigation of pharmacological regimens combined with focused ultrasound ablation surgery for alleviating dysmenorrhea in extrinsic adenomyosis]. Zhonghua Fu Chan Ke Za Zhi. 2026. PMID: 42045779. doi:10.3760/cma.j.cn112141-20250915-00433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。